STELLA PHARMA CORPORATION
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
| Fiscal Year | 2025 |
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
Full charting with technical indicators, candlestick, and more.
About STELLA PHARMA CORPORATION
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
| Ticker | 4888 |
| Exchange | TSE |
| Sector | Pharmaceutical |
| Industry | PHARMACEUTICAL |